

SUPPLEMENTARY TABLES

Supplementary Table S1: Statistical analysis of U87 cell cycle

1 X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout		
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	
	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.01	Control V Combo	0.001	
	Source of variation					P value					
	Drug					≤ 0.0001					
	Time					≤ 0.0001					
	Interaction					≤ 0.0001					
	S	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout	
Treatment		$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	
Control V Dasatinib		NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
Control V Crizotinib		0.001	Control V Crizotinib	0.01	Control V Crizotinib	NS	Control V Crizotinib	0.001	Control V Crizotinib	NS	
Control V Combo		0.01	Control V Combo	0.05	Control V Combo	NS	Control V Combo	0.01	Control V Combo	NS	
Source of variation					P value						
Drug					≤ 0.0001						
Time					≤ 0.0001						
Interaction					NS (0.23)						
2 X		48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout	
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	0.05	
	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	
	Source of variation					P value					
	Drug					NS (0.057)					
	Time					≤ 0.001					
	Interaction					≤ 0.0001					

(Continued)

T	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout		
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	0.01	Control V Crizotinib	NS	
	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	0.01	Control V Combo	0.01	
	Source of variation					P value					
	Drug					≤ 0.0001					
	Time					≤ 0.0001					
	Interaction					≤ 0.0001					
4 X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout		
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	
	Control V Combo	0.05	Control V Combo	0.001	Control V Combo	0.01	Control V Combo	0.001	Control V Combo	0.001	
	Source of variation					P value					
	Drug					≤ 0.0001					
	Time					≤ 0.0001					
	Interaction					≤ 0.0001					
T	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout		
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	NS	Control V Crizotinib	0.05	Control V Crizotinib	0.001	Control V Crizotinib	0.01	Control V Crizotinib	0.001	
	Control V Combo	NS	Control V Combo	NS	Control V Combo	0.001	Control V Combo	NS	Control V Combo	NS	
	Source of variation					P value					
	Drug					≤ 0.0001					
	Time					≤ 0.0001					
	Interaction					≤ 0.05					

(Continued)

8 X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout		
	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	NS	Control V Crizotinib	NS0	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	
	Control V Combo	NS	Control V Combo	NS	Control V Combination	0.001	Control V Combo	0.001	Control V Combo	0.001	
	Source of variation						<i>P</i> value				
	Drug						≤ 0.0001				
	Time						≤ 0.0001				
	Interaction						≤ 0.0001				

X denotes the quantity of DNA in the G1 phase of the cell cycle. 2X corresponds to the G2M phase while 4X and 8X to tetraploid and octoploid cells. S denotes DNA synthesis phase and T denotes transitional phase between the diploid, tetraploid and octoploid phases. Combo denotes combination and NS non-significant.

Supplementary Table S2: Statistical analysis of LN-18 cell cycle

1 X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout		
	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	
	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001	
	Source of variation						<i>P</i> value				
	Drug						≤0.0001				
	Time						≤0.0001				
	Interaction						NS (0.082)				

S	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout		
	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	0.01	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	0.05	Control V Crizotinib	NS	
	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	
	Source of variation						<i>P</i> value				
	Drug						≤0.0001				
	Time						NS (0.053)				
	Interaction						≤0.0001				

(Continued)

2 X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout	
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
	Control V Crizotinib	0.001	Control V Crizotinib	0.01	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS
	Control V Combo	0.001	Control V Combo	0.01	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS
	Source of variation					P value				
	Drug					≤ 0.0001				
	Time					≤ 0.0001				
	Interaction					≤ 0.0001				
	T	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout
Treatment		$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$
Control V Dasatinib		NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
Control V Crizotinib		NS	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS
Control V Combo		NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	0.05	Control V Combo	0.05
Source of variation					P value					
Drug					≤ 0.0001					
Time					≤ 0.0001					
Interaction					NS (0.097)					
4 X		48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001
	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001
	Source of variation					P value				
	Drug					≤ 0.0001				
	Time					≤ 0.0001				
	Interaction					≤ 0.0001				

(Continued)

T	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout	
	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001
	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	0.001	Control V Combo	0.001
	Source of variation					<i>P</i> value				
	Drug					≤0.0001				
	Time					≤0.0001				
	Interaction					≤0.0001				
	8X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout
Treatment		<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)
Control V Dasatinib		NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
Control V Crizotinib		NS	Control V Crizotinib	NS	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001
Control V Combo		NS	Control V Combo	NS	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001
Source of variation					<i>P</i> value					
Drug					≤0.0001					
Time					NS (0.56)					
Interaction					≤0.001					

X denotes the quantity of DNA in the G1 phase of the cell cycle. 2X corresponds to the G2M phase while 4X and 8X to tetraploid and octoploid cells. S denotes DNA synthesis phase and T denotes transitional phase between the diploid, tetraploid and octoploid phases. Combo denotes combination and NS non-significant.

Supplementary Table S3: Statistical analysis of U373 cell cycle

1 X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout	
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001
	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001
	Source of variation					P value				
	Drug					≤ 0.0001				
	Time					≤ 0.0001				
	Interaction					≤ 0.0001				
	S	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout
Treatment		$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$
Control V Dasatinib		NS	Control V Dasatinib	NS	Control V Dasatinib	0.05	Control V Dasatinib	NS	Control V Dasatinib	0.001
Control V Crizotinib		0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	NS	Control V Crizotinib	NS
Control V Combo		NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	0.01
Source of variation					P value					
Drug					≤ 0.0001					
Time					≤ 0.0001					
Interaction					≤ 0.0001					
2 X		48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS
	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.05	Control V Combo	NS	Control V Combo	NS
	Source of variation					P value				
	Drug					≤ 0.0001				
	Time					≤ 0.0001				
	Interaction					≤ 0.0001				

(Continued)

T	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout		
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	0.05	Control V Crizotinib	0.001	Control V Crizotinib	0.05	
	Control V Combo	NS	Control V Combo	NS	Control V Combo	0.05	Control V Combo	0.001	Control V Combo	NS	
	Source of variation					P value					
	Drug					≤ 0.0001					
	Time					≤ 0.0001					
	Interaction					≤ 0.0001					
4 X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout		
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	
	Control V Combo	0.01	Control V Combo	0.01	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001	
	Source of variation					P value					
	Drug					≤ 0.0001					
	Time					≤ 0.05					
	Interaction					≤ 0.0001					
T	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout		
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	0.01	Control V Crizotinib	0.01	Control V Crizotinib	0.001	Control V Crizotinib	0.05	Control V Crizotinib	0.001	
	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	0.001	
	Source of variation					P value					
	Drug					≤ 0.0001					
	Time					≤ 0.005					
	Interaction					≤ 0.05					

(Continued)

8 X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout	
	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.01	Control V Crizotinib	0.001
	Control V Combo	0.01	Control V Combo	0.01	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.001
	Source of variation					<i>P</i> value				
	Drug					≤0.0001				
	Time					≤0.0001				
	Interaction					≤0.01				

X denotes the quantity of DNA in the G1 phase of the cell cycle. 2X corresponds to the G2M phase while 4X and 8X to tetraploid and octoploid cells. S denotes DNA synthesis phase and T denotes transitional phase between the diploid, tetraploid and octoploid phases. Combo denotes combination and NS non-significant.

Supplementary Table S4: Statistical analysis of A172 cell cycle

1 X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout	
	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001
	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	NS	Control V Combo	0.001	Control V Combo	0.001
	Source of variation					<i>P</i> value				
	Drug					≤0.0001				
	Time					≤0.01				
	Interaction					≤0.0001				

S	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout	
	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)
	Control V Dasatinib	0.01	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
	Control V Crizotinib	NS	Control V Crizotinib	0.001	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS
	Control V Combo	NS	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	0.01	Control V Combo	NS
	Source of variation					<i>P</i> value				
	Drug					≤0.01				
	Time					≤0.0001				
	Interaction					≤0.0001				

(Continued)

2 X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout	
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001	Control V Crizotinib	0.001
	Control V Combo	0.001	Control V Combo	0.001	Control V Combo	NS	Control V Combo	0.001	Control V Combo	0.05
	Source of variation					P value				
	Drug					≤ 0.0001				
	Time					≤ 0.0001				
	Interaction					≤ 0.0001				
	T	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout
Treatment		$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$
Control V Dasatinib		NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
Control V Crizotinib		NS	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS
Control V Combo		NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS
Source of variation					P value					
Drug					≤ 0.05					
Time					≤ 0.0001					
Interaction					NS (0.91)					
4 X		48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout
	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$	Treatment	$P (\leq)$
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS
	Control V Crizotinib	NS	Control V Crizotinib	0.001	Control V Crizotinib	0.01	Control V Crizotinib	0.001	Control V Crizotinib	0.001
	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	0.01	Control V Combo	0.01
	Source of variation					P value				
	Drug					≤ 0.0001				
	Time					NS (0.108)				
	Interaction					≤ 0.01				

(Continued)

T	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout		
	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	
	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
	Control V Crizotinib	0.05	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS	
	Control V Combo	0.05	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	
	Source of variation					<i>P</i> value					
	Drug					NS (0.065)					
	Time					≤0.0001					
	Interaction					NS (0.36)					
	8X	48 hours		72 hours		24 hour washout		48 hour washout		72 hour washout	
Treatment		<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	Treatment	<i>P</i> (≤)	
Control V Dasatinib		NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	Control V Dasatinib	NS	
Control V Crizotinib		NS	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS	Control V Crizotinib	NS	
Control V Combo		NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	Control V Combo	NS	
Source of variation					<i>P</i> value						
Drug					NS (0.22)						
Time					≤0.01						
Interaction					NS (0.64)						

X denotes the quantity of DNA in the G1 phase of the cell cycle. 2X corresponds to the G2M phase while 4X and 8X to tetraploid and octoploid cells. S denotes DNA synthesis phase and T denotes transitional phase between the diploid, tetraploid and octoploid phases. Combo denotes combination and NS non-significant.